No matter how organisations feel about generative AI tools, the technology is truly transformative and is here to stay. AI solutions are the top emerging technology planned for deployment across enterprises and we need to ensure that the tools are used effectively in a customer-centric way – both for internal and external customers.
As the industry continues to evolve, the potential of generative AI to revolutionise processes and outcomes cannot be overlooked. These foundation models offer significant advantages in pharma, such as improving the drug discovery process, rapid content and idea generation, improved insights from textual data, improved efficiency (by automated long and repetitive tasks) and improved personalisation. Noteworthy examples include Bayer planning to use Gen AI tools to streamline the clinical trial process by enhancing analysis of extensive data sets 1. Similarly, Janssen intends to use Gen AI coding tools to speed up development cycles and testing of custom marketing tools 2.
Late in 2023, we laid out how humans must remain at the heart of AI in healthcare 3. Building on this approach, implementing AI at a large scale requires more than a surface-level understanding. It demands the preparedness of the entire organisation to harness the true value-add that generative AI brings to the table. There are 3 fundamental questions that leadership should answer when formulating a strong strategy for generative AI within its organisation: